查詢結果分析
來源資料
頁籤選單縮合
題名 | Metformin用於治療慢性C型肝炎=Role of Metformin in the Treatment of Chronic Hepatitis C |
---|---|
作者 | 黃慈婷; 林佩津; 曾碧萊; | 書刊名 | 藥學雜誌 |
卷期 | 30:4=121 2014.12[民103.12] |
頁次 | 頁85-90 |
分類號 | 415.5332、415.5332 |
關鍵詞 | 慢性C型肝炎; 胰島素阻抗; 腺苷單磷酸活化蛋白激酶; AMPK; Metformin; |
語文 | 中文(Chinese) |
中文摘要 | 在目前慢性C型肝炎標準治療藥品組合:干擾素和瑞比達 (ribavirin;Rebetol) 使 用後,能夠達到成功治癒的比例並不高,其中胰島素阻抗是治療失敗的一個很重要 的因素,造成阻抗原因複雜包括:促發炎物質細胞激素 (cytokines)、腫瘤壞死因子 (tumor necrosis factor TNF)、間白質素 (interleukin-6;IL-6) 等;metformin 是 AMPK (AMP-activated protein kinase) 致效劑,是一個可以減少胰島素阻抗及增加胰島素敏感 性的降血糖藥品,本文旨在回顧 metformin 應用於慢性C型肝炎所引起胰島素阻抗的 機轉及提升C型肝炎治癒率並降低復發,同時減少肝硬化肝炎的發生。 |
英文摘要 | After introducing the combination of interferon and ribavirin (Rebetol) for the treatment of chronic hepatitis C, the achievement of the eradication rate is not high, one of the important factors of treatment failure is insulin resistance, which might be due to complex mechanism, the factors involved in the mechanism are as following: pro-inflammatory cytokines substances (cytokines), tumor necrosis factor (TNF), Interleukin-6 (IL-6) etc; while metformin is an AMPK agonist. It is well known that it can reduce insulin resistance and increase insulin sensitivity of tissue. The goal what we want to achieve is how to apply metformin for treatment of insulin resistance in chronic hepatitis C patients. Consequently, it would be more cost-saving and fewer side effects to improve cure rate and decrease relapse rate. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。